See more : Proxene Tools Co., Ltd. (6904.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of Universe Pharmaceuticals INC (UPC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Universe Pharmaceuticals INC, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- BTU Metals Corp. (BTU.V) Income Statement Analysis – Financial Results
- Rotor Acquisition Corp. (ROT) Income Statement Analysis – Financial Results
- China Zenith Chemical Group Limited (0362.HK) Income Statement Analysis – Financial Results
- V2Y Corporation Ltd. (V2Y.SI) Income Statement Analysis – Financial Results
- GOAT Industries Ltd. (BGTTF) Income Statement Analysis – Financial Results
Universe Pharmaceuticals INC (UPC)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.universe-pharmacy.com
About Universe Pharmaceuticals INC
Universe Pharmaceuticals INC, a pharmaceutical company, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party producers, including biomedical drugs, medical instruments, traditional Chinese medicine pieces products, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was incorporated in 2019 and is based in Ji'An, China. Universe Pharmaceuticals INC is a subsidiary of Sununion Holding Group Limited.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 32.31M | 40.14M | 47.98M | 30.70M | 33.23M | 28.51M |
| Cost of Revenue | 21.99M | 18.25M | 22.66M | 16.61M | 19.82M | 15.11M |
| Gross Profit | 10.32M | 21.89M | 25.33M | 14.09M | 13.41M | 13.41M |
| Gross Profit Ratio | 31.93% | 54.53% | 52.78% | 45.90% | 40.35% | 47.03% |
| Research & Development | 4.86M | 7.64M | 5.47M | 583.13K | 618.44K | 789.38K |
| General & Administrative | 2.22M | 1.75M | 3.30M | 1.24M | 713.65K | 704.87K |
| Selling & Marketing | 6.78M | 19.08M | 2.97M | 1.56M | 1.58M | 1.68M |
| SG&A | 9.00M | 20.84M | 6.27M | 2.80M | 2.29M | 2.39M |
| Other Expenses | -17.53K | 430.31K | -80.43K | 365.77K | 445.77K | 5.01K |
| Operating Expenses | 13.84M | 28.91M | 11.74M | 3.74M | 3.36M | 3.65M |
| Cost & Expenses | 35.84M | 47.16M | 34.39M | 20.35M | 23.18M | 18.75M |
| Interest Income | 0.00 | 0.00 | 239.55K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 156.79K | 162.40K | 101.60K | 123.76K | 129.27K | 164.92K |
| Depreciation & Amortization | 508.79K | 533.95K | 446.88K | 410.08K | 418.43K | 452.73K |
| EBITDA | -3.22M | -7.33M | 14.20M | 10.61M | 10.17M | 10.11M |
| EBITDA Ratio | -9.95% | -15.94% | 29.15% | 34.95% | 31.59% | 35.91% |
| Operating Income | -3.53M | -7.02M | 13.59M | 10.25M | 9.75M | 9.66M |
| Operating Income Ratio | -10.92% | -17.49% | 28.32% | 33.39% | 29.35% | 33.87% |
| Total Other Income/Expenses | -322.80K | -545.35K | 88.34K | -151.29K | -99.77K | -138.28K |
| Income Before Tax | -3.85M | -7.98M | 13.68M | 10.10M | 9.65M | 9.52M |
| Income Before Tax Ratio | -11.91% | -19.89% | 28.51% | 32.90% | 29.05% | 33.38% |
| Income Tax Expense | 2.31M | 752.42K | 2.36M | 2.54M | 2.10M | 1.92M |
| Net Income | -6.16M | -8.74M | 11.32M | 7.56M | 7.55M | 7.60M |
| Net Income Ratio | -19.08% | -21.76% | 23.59% | 24.62% | 22.73% | 26.66% |
| EPS | -1.70 | -2.41 | 3.12 | 2.06 | 2.05 | 0.36 |
| EPS Diluted | -1.70 | -2.41 | 3.12 | 2.06 | 2.05 | 0.36 |
| Weighted Avg Shares Out | 3.63M | 3.63M | 3.63M | 3.68M | 3.68M | 21.00M |
| Weighted Avg Shares Out (Dil) | 3.63M | 3.63M | 3.63M | 3.68M | 3.68M | 21.00M |
Universe Pharmaceuticals INC Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
“I Will Make UPC Great Again!”—UPC Presidential Hopeful Othieno Vows as He Praises Obote’s Legacy
Universe Pharmaceuticals INC Reports Financial Results for The First Six Months of Fiscal Year 2024
UPC Tasks President Museveni to Produce Evidence of Vote Rigging in Courts of Law
UPC Concerned over Welfare of Medical Interns
UPC Calls on Government to Impact Skills Development Education in Youth
UPC Raises Red Flag on Road Carnage, City Robberies
UPC Condemns Re- Arrest of Legislator Released on Bail for Corruption Charges
UPC Calls on Government to Address Workers’ Rights on International Labour Day
Place Interest of the Common Man at the Centre – Jimmy Akena
Source: https://incomestatements.info
Category: Stock Reports